WO2013189778A1 - Bag3 as biochemical serum and tissue marker - Google Patents

Bag3 as biochemical serum and tissue marker Download PDF

Info

Publication number
WO2013189778A1
WO2013189778A1 PCT/EP2013/061976 EP2013061976W WO2013189778A1 WO 2013189778 A1 WO2013189778 A1 WO 2013189778A1 EP 2013061976 W EP2013061976 W EP 2013061976W WO 2013189778 A1 WO2013189778 A1 WO 2013189778A1
Authority
WO
WIPO (PCT)
Prior art keywords
bag3
antibodies
cancer
serum
bag
Prior art date
Application number
PCT/EP2013/061976
Other languages
French (fr)
Inventor
Maria Caterina Turco
Original Assignee
Biouniversa S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2876922A priority Critical patent/CA2876922C/en
Priority to KR1020157001313A priority patent/KR102150903B1/en
Priority to PL13728180T priority patent/PL2861618T3/en
Priority to CN201380032138.3A priority patent/CN104507965B/en
Priority to AU2013279604A priority patent/AU2013279604B2/en
Priority to BR112014031958A priority patent/BR112014031958A2/en
Application filed by Biouniversa S.R.L. filed Critical Biouniversa S.R.L.
Priority to JP2015517672A priority patent/JP6654432B2/en
Priority to EP13728180.4A priority patent/EP2861618B1/en
Priority to ES13728180T priority patent/ES2795981T3/en
Publication of WO2013189778A1 publication Critical patent/WO2013189778A1/en
Priority to IN10561DEN2014 priority patent/IN2014DN10561A/en
Priority to US14/572,654 priority patent/US10359433B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/101—Temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure concerns the field of diagnostic biological markers. Specifically the disclosure relates to anti-BAG3 antibodies for use as biological markers for the diagnosis of a pathological state. Furthermore, the disclosure involves specific ELISA methods and kits, for detecting and evaluating, anti-BAG3 antibodies or BAG3/antibody complexes in a biological sample.

Description

BAG3 AS BIOCHEMICAL SERUM AND TISSUE MARKER
DESCRIPTION
The present invention concerns anti-BAG3 antibodies for use as biochemical markers in the diagnosis of a pathological state.
STATE OF THE ART
BAG3 (RefSeq: NP_ 004272; Gene ID 9531) is a 74 kDa cytoplasmic protein particularly concentrated in the rough endoplasmic reticulum. BAG3 protein belongs to the family of co-chaperones that interact with the ATPase domain of the heat shock protein HSP70 through the structural domain known as BAG domain (110-124 amino acids) . In addition to the BAG domain, BAG3 contains a WW domain and a proline-rich repeat (PXXP) , that can mediate binding to other proteins. Furthermore, two conserved IPV ( Ile-Pro-Val ) motifs are located between the WW and the PXXP regions and mediate BAG3 binding to HspB8, a member of the HspB family of molecular chaperones. Therefore BAG3, due to the adaptor nature of its multidomain structure, can interact with different partner proteins. bag3 gene expression is constitutive in a few normal cell types, including myocytes, and in several primary tumours or tumour cell lines. Moreover it can be induced by a variety of stressors: indeed stressful stimuli activate the heat shock transcription factor (HSF) 1, that is responsible for the expression of stress- activated genes, including bag3 (Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco MC . BAG3 : a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011; 2: el41) . Evidence indicates that BAG3 has a role in sustaining cell survival, by modulating, in either Hsp70- dependent or -independent fashion, the levels or localisation of apoptosis- regulating proteins, such as ΙΚΚγ, Bax or BRAF, depending on cell context .
BAG3 protein appears to be expressed during cardiomyoblasts differentiation and to sustain myogenin expression. These findings indicate an involvement of BAG3 in late heart development (De Marco M, Turco MC, Rosati A. BAG3 protein is induced during cardiomyoblast differentiation and modulates myogenin expression. Cell Cycle. 2011; 10: 850-852). Moreover, in cardiomyocytes BAG3 has been shown to localize at Z-disc and interact with the actin capping protein, CapZpl, stabilizing myofibril structure and possibly preserving myofibrillar integrity during mechanical stress. BAG3 mutations can impair the Z-disc assembly and increase the sensitivity to stress-induced apoptosis. In keeping with the role of BAG3 in the survival and myofibrillar integrity in cardiocytes and, in general, in muscle cells, mutations in bag3 gene have been associated with some forms of myofibrillar myopathy and dilated cardiomyopathy.
Up to now both a cytoplasmic BAG3 and soluble serical form of BAG3 have been detected and found associated with different pathologies, as well as more generally to cell survival. The need and importance is increasingly felt for the identification of a biological marker which allows the rapid identification of such pathologies, without having the disadvantages of being associated with invasive diagnostics in a surprisingly specific and sensitive manner, and/or that can allow to early detect the pathology, monitor the effect of therapy, predict the risk of complication, perform an informative follow-up .
SUMMARY OF THE INVENTION
The present invention concerns anti-BAG3 antibodies for use as biochemical markers in the diagnosis of a pathological state.
Preferably said anti-BAG3 antibodies are bound to soluble BAG3 to form immune complexes.
According to a preferred embodiment of the present invention said diagnosis is in vitro or ex vivo .
A further aspect of the present invention is that the recipient of said diagnosis is a mammalian, preferably a human.
As will be further described in the detailed description of the invention, the use of the anti-BAG-3 antibodies of the present invention has the advantages of being specific for a pathological state selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
According to an embodiment of the invention, said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
According to another embodiment of the invention, said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
A further embodiment of the present invention is a method for detecting the presence of an anti- BAG3 antibody or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex in a biological sample, comprising the steps of:
a. obtaining a biological sample, consisting of serum, plasma, urine or saliva,
b. determining the presence of anti-BAG3 or BAG3 associated antibodies in the biological sample .
According to a preferred embodiment, the method of the present invention further comprises the additional step of :
c. comparing the values obtained from biological sample with reference values or with the values obtained from healthy donors .
In a preferred embodiment, said determination step b. is performed by an ELISA test.
According to a preferred embodiment of the present invention said serum, plasma, urine or saliva is from a mammalian, preferably a human. According to a preferred embodiment in the method of the present invention the presence of said anti-BAG3 antibody or said immune complex is associated with a pathological condition.
Preferably, said pathological condition is selected from the group consisting of a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues .
Preferably said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease .
According to a preferred embodiment of the present invention said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer .
A further embodiment of the present invention is an ELISA kit, comprising a BAG3 recombinant protein or BAG3-specific mouse monoclonal antibodies AC-1, AC-2 AC-3, AC-4, AC-5, AC-rbla, AC-rblb, AC-rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC- rb4a and AC-rb4b for capturing soluble BAG3 and antibodies able to recognize human immunoglobulins, as well as its use for the detection of anti-BAG3 antibodies or anti-BAG3 antibodies bound to soluble BAG3 to form an immune complexes in a biological sample.
Preferably said biological sample is a serum, plasma, urine or saliva sample. In a preferred embodiment of the present invention said serum, plasma, urine or saliva sample is from a mammalian, preferably a human. The invention still further relates to a immunohistochemistry (IHC) kit for the detection of BAG3 protein in a biological sample, wherein said biological sample is preferably a tissue sample, comprising BAG3- specific antibodies and reagents including probes needed for the staining .
BRIEF DESCRIPTION OF THE DRAWINGS
The characteristics and advantages of the present invention will be apparent from the detailed description reported below, from the Examples given for illustrative and non-limiting purposes, and from the annexed Figures 1-10, wherein:
Figure 1.
Figure 1A: detection of BAG3 protein in supernatants from cultured cardiomyocytes . Human (HCMa) and rat (H9c2) cardiomyocytes at 80% confluency were incubated with or without 10% FBS for 16 hours at 37°C in a 5% CO2 atmosphere. Supernatants were dialyzed in a buffer containing 50 mM NaCl and 0.05% IGEPAL, lyophilized, resuspended in 1 ml of RIPA buffer (50 mM Tris HC1 pH 7.6, 150 mM sodium chloride, 2 mM sodium orthovanadate, 4 mM EDTA, lOmM sodium pyrophosphate, 1% NP-40, 0.1% sodium deoxycholate ) , and analyzed with anti-BAG3 or anti-GAPDH antibodies by western blotting.
Figure IB: detection of BAG3 protein in exocytic vesicles. Surnatants obtained from H9c2 cells were subjected to sequential centrifugations : (i) 2' 000xg for 15 min, to remove cells; (ii) 10'OOOxg for 30 min, to remove cellular debris; (iii) 150' 000xg for 90 min, to pellet exocytic vesicles. The pellet was washed once in PBS at 150' 000xg for 90 min and analyzed with the anti- BAG3 TOS-2 polyclonal antibody in comparison with a whole-cell lysate by western blot. Rab-4 was analyzed as a marker for exocytic vesicles. GAPDH, a cytosolic protein, was analyzed as a control .
Figure 1C: Sera from two healthy donors and from two patients affected by chronic heart failure were analyzed with the anti-BAG3 antibody TOS-2 polyclonal antibody in western blotting.
Figure ID: Bands obtained in two patients affected by chronic heart failure were excised from the gel and its identity analyzed by mass spectrometry using the program MASCOT.
Figure 2.
Figure 2A: detection of BAG3 protein in sera from CHF patients. BAG3 recombinant protein and whole- cell lysate from HCMa cells were analyzed by western blotting with serum (1:40) obtained from a patient with heart failure. Analysis with serum from a healthy donor was performed as negative control .
Figure 2B: detection of anti-BAG3 antibodies by ELISA test. Sera from 50 CHF patients (with ejection fraction < 60%) were compared with sera from 50 healthy donor for the presence of anti- BAG3 antibodies in a specific ELISA test. Results are plotted as arbitrary units.
Figure 2C: ROC analysis of ELISA test results. Cut-off on 0.083 A.U. results in 74% sensitivity and 68% specificity.
Figure 3.
Figure 3A: Confocal microscopy analysis of direct fluorescence performed for detection of rBAG3- FITC binding to HCMa cells (a, b, c) and J774 Al cells (d, e, f, g, h, i) . BAG3 recombinant protein and purified BSA (albumin from bovine serum purchased from SIGMA) were conjugated to FITC using the FluoroTag FITC Conjugation Kit purchased from SIGMA following the manufacturer instructions. Equal amount of rBAG3-FITC (b, e) and BSA-FITC (h) proteins, calculated following the manufacturer instructions, were added in HCM and J774 Al culture media with 0.1 % NaN3 for 1 h. β-integrin was analyzed as control (a, d, g) . Cells were analyzed by a Zeiss LSM confocal microscope. Merged images are shown in c, f and i .
Figure 3B: BAG3 binds macrophages. J774 Al macrophages (lxlO6 cells/ml) were incubated with different concentration of Fitc-BAG3 protein (7, 14 and 70 nm) . FITC-BSA (70 nM) was used as a negative control (grey) . Cells fluorescence was analyzed by flow cytometry.
Figure 3C panel a - Analysis of Cox-2 and iNOS levels in J774 Al macrophages incubated with BAG3. J774 Al cells at 80% confluency were incubated with control medium, BSA, LPS or rBAG3, for 20 hours. Polymixin was added where indicated to verify that the effects of E. coli- derived rBAG3 were independent from the presence of contaminating endotoxin. Cox-2 and iNOS expression were analyzed in cell lysates by Western blotting.
Figure 3C panel b - Analysis of nitrite release from J774 Al macrophages incubated with BAG3. J774 Al cells at 80% confluency were incubated with control medium, BSA, LPS or rBAG3 for 24 hours. 100 μΐ of supernatants from each sample were incubated with 100 μΐ of Griess reagent; the optical density at 550 nm (OD550) was measured with a Beckman DU62 spectrophotometer. Nitrite concentration was evaluated by comparing the OD550 of the sample with that of a standard curve of sodium nitrite.
Figure 3C panel c - Analysis of IL-6 release from J774 Al macrophages incubated with BAG3. J774 Al cells at 80% confluency macrophages were incubated with control medium, BSA, LPS or recombinant BAG3 for 5 hours. BAG3 peptides (peptide 1, peptide 2, peptide 3, peptide 4 or scrambled peptide) 625 nM were added where indicated to verify their ability to block BAG3 activity. IL-6 production was measured in cell culture medium using an ELISA test. IL-6 concentration was evaluated by comparing the OD of the sample with that of a standard curve of recombinant IL-6.
Figure 4 .
Figure 4A:
Representative images of BAG3 staining using the monoclonal anti-BAG3 antibody AC-1 in normal pancreas tissue. Sections were counterstained with hematoxylin. Staining revealed a moderate positivity of Langerhans islets, while normal pancreatic ducts and pancreatic acinar cells had no BAG3 expression.
Figure 4B :
Representative images of BAG3 low positive and BAG3 high positive tumor samples stained using a monoclonal anti-BAG3 antibody revealed with a biotinylated secondary antibody. Sections were counterstained with hematoxylin. Two different magnifications are shown: 100X (left panels) and 400X (right panels) . We assigned a score based on the proportion of positive cancer cells in the sample by counting the number of positive cells over the total cancer cells in 10 non-overlapping fields using a 400x magnification. The median percentage of BAG3 positive cells, calculated as described, was 40% and this value was used as a cut-off to separate low and high positive samples .
Figure 4C:
Survival curves were made comparing 39 patients with low BAG3 staining (≤40% of positive cells) and 27 patients with high BAG3 staining (>40% of positive cells). All patients analyzed underwent R0 resection of the pancreatic adenocarcinoma. Median survival increases from 12 months in the high positive group to 23 months in the low positive group. Log-rank test p-value=0.0013.
Figure 5 . Representative image of BAG3 staining in synovial tissues from several rheumatoid arthritis. BAG3 positivity is observed in synovial fibroblasts and inflammatory infiltrates. Sections were counterstained with hematoxylin.
Figure 6.
Representative image of BAG3 staining in normal urocystis that resulted negative and in transitional cell bladder carcinoma that resulted highly positive for BAG3 in cytoplasm of tumor cells. Sections were counterstained with hematoxylin .
Figure 7.
Figure 7A:
bag3 mRNA relative expression evaluated by qRT- PCR is shown in a graph where values are reported as mean + S.D. The blue line represents the median value calculated.
Figure 7B :
Survival analysis was made for all patients analyzed with qRT-PCR. 13 patients with high bag3 expression had shorter survival (median survival =19.0 months) as compared to 12 patients with low bag3 expression (median survival = 32.0 months) . Log-rank test p-value = 0.0198.
Figure 8.
Figure 8A:
Pancreatic cancer cell lines (PSN1, Capan-1, AsPC-1, PANC-1 and MIA PaCa-2 ) were treated with different concentrations of gemcitabine as indicated in the graph. After 48 hours, apoptotic cell death was analyzed. Graph depicts mean percentage of Sub G0/G1 cells (± S.D.). Data are representative of three independent experiments. Figure 8B:
Western blot analysis of BAG3 in pancreatic cancer cell lines; GAPDH housekeeping protein contents were used to monitor equal loading conditions .
Figure 8C:
MIA PaCa-2 and PANC-1 cell lines were treated with 2 μΜ gemcitabine (GEM) for the indicated times BAG3 protein expression levels were monitored by western blot .
Figure 8D:
bag3 mRNA levels were analyzed by RT-PCR; graph depicts relative bag3 mRNA levels (± S.D.) and data are representative of three indipendent experiments .
Figure 8E :
MIA PaCa-2 and PANC-1 cell lines were transfected with BAG3 siRNA or a non- targeted siRNA (NTsiRNA) for 72 hours and then treated with 2 μΜ gemcitabine (GEM) for 24h. BAG3 levels were analyzed by western blot and GAPDH levels were detected to monitor equal loading conditions.
Figure 8F :
MIA PaCa-2 and PANC-1 cells were transfected as described above and treated with 2 μΜ gemcitabine (GEM) for 24h or 48h. Apoptotic cell death was analyzed as described. Graph depicts mean percentage of Sub G0/G1 cells (± S.D.). Data are representative of three independent experiments. Figure 9. Figure 9A: Detection of BAG3 specific immuno- complexes by ELISA test. Sera from 55 pancreatic adenocarcinoma patients were compared with sera from 51 healthy donors for the presence of BAG3 specific immune-complexes in a specific ELISA test. Results are plotted as arbitrary units +S . E .
Figure 9B: ROC analysis of ELISA test results. Cut-off on 0.183 A.U. results in 65% sensitivity and 78% specificity.
Figure 10.
Detection of BAG3-specific antibodies in patients sera from 49 female subjects at 0-1 years pre- diagnosis for pancreatic adenocarcinoma were compared with sera from 235 female control subjects sera for the presence of BAG3 specific antibodies in a specific ELISA test. Control sera were about five for each case subjects and age matched with the respective case. Others time points included: 53 subjects at 1-2 years pre- diagnosis for PDAC compared to 251 controls; 44 subjects at 2-3 years pre-diagnosis for PDAC compared to 212 controls; 42 subjects at 3-4 years pre-diagnosis for PDAC compared to 187 controls .
Results are plotted as arbitrary units _+S . P value was calculated with student's t test.
DETAILED DESCRIPTION OF THE INVENTION
The present invention concerns anti-BAG3 antibodies for use as biochemical markers in the diagnosis of a pathological state.
With the term "diagnosis" in the present invention we refer to medical diagnosis (often simply termed diagnosis) that refers to the process of attempting to determine or identify a possible disease or disorder. The diagnosis of the present invention encompasses also the early diagnosis
With the term "early diagnosis" we refer to the capacity of the test to discriminate a pathological state before specific or aspecific symptoms .
Anti-BAG3 antibodies have now been advantageously detected in serum, plasma, urine or saliva. Until now such antibodies had never been found in serum either in physiological or pathological condition. The detection of anti-BAG3 antibodies in serum has the advantage of being a rapid and non-invasive technique be exploited for diagnostic, early diagnosis and prognostic purposes, risk stratification, as a tool for the identification and for monitoring therapies.
A further advantage of the detection of antibodies is that a very small amount of serum is required for the detection. In fact, soluble BAG3 protein can also be detected in the serum of patients suffering from some pathologies, but the amount of serum requested for the detection of the soluble protein is much higher than that required for the detection of antibodies. Furthermore, it is possible that soluble BAG3 protein levels can be much lower than those of antibodies and/or that, respect to soluble BAG3 protein, antibodies can be detectable in earlier phases of specific pathologies and/or can more efficiently predict risk of complications or monitor the effects of therapies.
A further embodiment of the present invention is that said anti-BAG3 antibodies can be advantageously detected in different biological samples selected from serum, plasma, urine or saliva .
In the present invention, by serum is intended the component of blood that is neither a blood cell nor a clotting factor; it is the blood plasma with the fibrinogens removed. Serum includes all proteins not used in blood clotting (coagulation) and all the electrolytes, antibodies, antigens, hormones, and any exogenous substances .
In the present invention, by plasma is intended the straw-coloured/pale-yellow liquid component of blood that normally holds the blood cells in whole blood in suspension. It contains clotting factors, such as fibrinogens.
In a further embodiment, the invention provides the use of anti-BAG3 antibodies as biochemical markers, wherein said anti-BAG3 antibodies are bound to soluble BAG3 to form immune complexes. Anti-BAG3 antibodies, either free or bound to soluble BAG3 to form immune complexes have advantageously been now detected in a biological sample, and may be used as a marker in the diagnosis of a pathological condition. The detection of such antibodies and/or immune complexes in a biological sample also has the advantage of being a rapid and non-invasive technique for diagnostic and/or prognostic purposes .
According to a preferred embodiment of the present invention said diagnosis is in vivo or ex vivo .
A further embodiment of the present invention is that recipient of said diagnosis is a mammalian, preferably a human.
In the present invention, by immune complex or protein/antibody complex is intended the integral binding of an antibody to a soluble antigen, the bound antigen acting as a specific epitope, bound to an antibody is referred to as a singular immune complex.
Such immune complexes have the same advantages seen as for the detection of antibodies, since a very small amount of serum is required also for the detection of the immune complex. The amount of serum required for the detection of soluble BAG3 is much higher also than that required for the detection of the protein/antibody (immune) complexes. Immune complexes as well as free antibodies can be detectable in earlier phases of specific pathologies and can more efficiently predict risk of complications or monitor the effects of therapies.
A still further embodiment of the invention is the use of anti-BAG3 antibodies or said immune complexes (formed by anti-BAG3 antibodies bound to soluble BAG3 ) as biological markers of a pathological state, wherein said pathological state is a heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
Preferably said heart disease is selected from the group consisting of: angina pectoris, preinfarction angina, ischemia, myocardial infarction, heart failure, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
According to a preferred embodiment of the present invention said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer .
A further embodiment of the present invention is a method for detecting the presence of an anti- BAG3 antibody or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex in a biological sample, comprising the steps of:
a. obtaining a biological sample, consisting of serum, plasma, urine or saliva,
b. determining the presence of anti-BAG3 or BAG3 associated antibodies in the biological sample .
The method according to the present invention has the advantage of allowing to detect significant differences between anti-BAG3 antibodies and/or BAG3 /antibodies complexes between healthy individuals and patients affected by BAG3- involving pathologies. The proposed assay method allows a statistically significant separation of the group of cardiac patients from the group of healthy people. It can also stratify such patients with heart disease in subgroups of patients at increased risk (heart failure, HF). In a still further aspect the invention relates to a method for detecting the presence of an anti-BAG3 antibody in a biological sample or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex, further comprising the step of:
c. comparing the values obtained from the biological sample with reference values or with the values obtained from healthy donors . In a preferred aspect the method according to the present invention is a method wherein said determination step b. is performed by an ELISA test .
According to a preferred embodiment in the method of the present invention said serum, plasma, urine or saliva is from a mammalian, preferably a human .
The method according to the present invention has the advantage of allowing the rapid and noninvasive detection of the biological markers allowing the evaluation of pathologies, risks for diseases and/or their complications, and monitoring of therapies.
According to a further aspect the invention relates to a detection method wherein the presence of said anti-BAG3 antibody or said anti- BAG3 antibody bound to soluble BAG3 to form an immune complex is associated with a pathological condition . In a preferred embodiment said pathological condition is chosen from the group consisting of heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues. In particular said heart disease is selected from the group consisting of: angina pectoris, pre-infarction angina, myocardial infarction, ischemia, heart failure, acute coronary disease, acute heart failure, chronic heart failure or iatrogenic heart disease.
According to a preferred embodiment of the present invention said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer .
The invention further relates to an ELISA kit for the detection of anti-BAG3 antibodies or anti- BAG3 antibodies bound to soluble BAG3 to form an immune complexes in a biological sample.
The ELISA kit according to the present invention comprises a BAG3 recombinant protein for capturing anti-BAG3 antibodies or BAG3- specific mouse monoclonal antibodies AC-1, AC-2, AC-3, AC- 4, AC-5, AC-rbla, AC-rblb, AC-rb2a, AC-rb2b, AC- rb3a, AC-rb3b, AC-rb4a and AC-rb4b, for capturing soluble BAG3 and antibodies able to recognize human immunoglobulins.
Such antibodies can be enzyme-linked antibodies able to recognize human immunoglobulins.
The invention also relates to a kit for the detection of BAG3-associated antibodies in a biological sample and is performed by ELISA with BAG3-specific mouse monoclonal antibodies AC-1, AC-2, AC-3, AC-4, AC-5, AC-rbla, AC-rblb, AC- rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC-rb4 and AC- rb4b, for capturing soluble BAG3 and enzyme- linked antibodies for the detection able to recognize human immunoglobulins.
Preferably said biological sample is a serum, plasma, urine or saliva sample.
In a preferred embodiment of the present invention said serum, plasma, urine or saliva sample is from a mammalian, preferably a human. The invention still further relates to a immunohistochemistry (IHC) kit for the detection of BAG3 protein in a biological sample, wherein said biological sample is preferably a tissue sample. Tissue samples can be biopsies, frozen tissues, paraffin embedded tissues.
The IHC kit according to the present invention comprises BAG3- specific antibodies and reagents including probes needed for the staining.
Said BAG3- specific antibodies can be mouse monoclonal antibodies AC-1, AC-2 and AC-3 and/or enzyme-linked antibodies for the detection able to recognize mouse immunoglobulins.
In particular, the IHC kit advantageously allows to reveal BAG3 protein in 100% of pancreatic carcinoma tissue samples from patients that undergo pancreas resection and is expressed in most bladder carcinoma samples. Furthermore, BAG3 protein can be revealed with the kit for BAG3 detection by IHC also in normal pancreas tissue in Langerhans islets while other normal tissues result negative (such for example normal urocystis). BAG3 positivity can be also observed in synovial fibroblasts and inflammatory infiltrates in rheumatoid arthritis tissue samples .
Long-term survival of patients affected by PDAC is very poor: only about 4% of patients will live 5 years after diagnosis. Indeed, surgical reception is presently the only chance of cure, but only approximately 20% of patients are diagnosed with resectable disease; furthermore, in a large proportion (about 80%) of such subset of patients the metastatization process is already occurring at diagnosis, and indeed distant metastases appear after surgical resection. Hence we need to better understand early stages in the development of pancreatic cancer and identify molecules that can allow detecting them. Also, markers that can allow a better prognosis and help the choice of therapies are highly required.
Advantageously the BAG3 IHC kit allows the identification of the prognosis of PDAC patients. It was seen that the intensity of BAG3 expression identified by IHC, correlates with patients' survival. Therefore it can be used for both prognosis and for making a choice of therapy.
A still further aspect of the invention is a kit for the detection of BAG3 gene expression in a biological sample comprising a set of amplification primers. Preferably said amplification primers are suitable for the detection by quantitative real-time RT-PCR.
Specific primers bag3 primers according to primer sets 1 to 5, which are described below and identified by the SEQ ID NO. 1 to SEQ ID NO. 10, allow the detection and quantification of BAG3 expression by quantitative real-time PCR.
Primer set 1
fw: SEQ ID NO. 1: AACGGTGACCGCGACCCTTT ;
rev: SEQ ID NO. 2: CCTTCCCTAGCAGGCGGCAG
Primer set 2
fw: SEQ ID NO. 3: CCGGCTGGCCCTTCTTCGTG;
rev: SEQ ID NO. 4: CAGCCTAGAGCCCTCCCGGG
Primer set 3
fw: SEQ ID NO. 5: GTCACCTCTGCGGGGCATGC ;
rev: SEQ ID NO. 6: GGTGACTGCCCAGGCTGCTC
Primer set 4
fw: SEQ ID NO. 7: CCAGCCTCCCACGGACCTGA;
rev: SEQ ID NO. 8: CTGGTGACTGCCCAGGCTGC
Primer set 5
fw: SEQ ID NO. 9: CAGGAGCAGCACGCCACTCC ;
rev: SEQ ID NO. 10: TGGTCCAACTGGGCCTGGCT .
The RT-PCR kit for bag3 mRNA detection in a biological sample allows to correlate the levels of bag3 gene expression with patients' survival and can be used for prognosis and for choice of therapy. Preferably said biological sample is a tissue sample.
A still further aspect of the invention is represented by anti-BAG3 monoclonal antibodies, their fragments, and peptides corresponding to specific aminoacidic sequences of BAG3 protein that are able to block macrophage activation and can therefore be used for therapy of inflammatory, oncologic or other diseases involving macrophage activation. See in particular Figure 3 and Table I.
This invention relates to the use of BAG3- specific mouse monoclonal antibodies AC-1, AC-2 and AC-3 or same modified as F(ab), F(ab')2, F(ab) or humanized; or peptides comprising sequences as follows:
PEP 1: DRDPLPPGWEIKIDPQ (SEQ ID NO. 11)
PEP2 : SSPKSVATEERAAPS (SEQ ID NO. 12)
PEP3 : DKGKKNAGNAEDPHT (SEQ ID NO. 13)
PEP4: NPSSMTDTPGNPAAP (SEQ ID NO. 14)
as molecules able to bind and/or block soluble
BAG3 effects.
EXAMPLES
Example 1.
Serum deprivation-induced stress in cultured human primary cardiomyocytes and the rat cardiomyocyte cell line H9c2
Cardiomyocytes are known to release protective factors in mounting a response against stressful agents. Since stress- induced proteins, such as Hsp70, Hp27, Hsp90 and others, although exerting an intracellular activity, can also be secreted in response to stress, BAG3 release by cardiomyocytes was analyzed in stressful conditions. For this purpose, we analyzed the effect of serum deprivation- induced stress in cultured human primary cardiomyocytes or the rat cardiomyocyte cell line H9c2. As shown in Figure 1, we could detect BAG3 protein in the supernatants of cardiomyocytes exposed to serum deprivation for 16 h (Figure 1A) . Since at that time point cell survival was not affected by serum deprivation (results not shown) , we discarded the hypothesis that BAG3 release was due to cell necrosis. Therefore we verified whether BAG3 was present in exocytic vesicles. Indeed, by isolating extracellular vesicles through a differential centrifugation procedure (16), we found that they contained BAG3 protein (Figure IB) .
To further verify the existence of a soluble form of BAG3, we investigated its presence in two blood sera from patients affected by chronic heart failure (CHF) . Through western blot analysis, we could identify a band recognized by anti-BAG3 antibody. We excised the band and subjected it to mass spectrometry, confirming its identity (Figure 1C). This evidence confirmed that the protein could be detected in an extracellular form. We could not detect the protein in sera from healthy donors (Figure 1C) . Peptides recognized and matched by mass spectrometry on the entire BAG3 protein sequence are indicated in bold:
MSAATHSPMM QVASGNGDRD PLPPGWEIKI DPQTGWPFFV DHNSRTTTWN DPRVPSEGPK ETPSSANGPS REGSRLPPAR EGHPVYPQLR PGYIPIPVLH EGAENRQVHP FHVYPQPGMQ RFRTEAAAAA PQRSQSPLRG MPETTQPDKQ CGQVAAAAAA QPPASHGPER SQSPAASDCS SSSSSASLPS SGRSSLGSHQ LPRGYISIPV IHEQNVTRPA AQPSFHQAQK THYPAQQGEY QTHQPVYHKI QGDDWEPRPL RAASPFRSSV QGASSREGSP ARSSTPLHSP SPIRVHTWD RPQQPMTHRE TAPVSQPENK PESKPGPVGP ELPPGHIPIQ VIRKEVDSKP VSQKPPPPSE KVEVKVPPAP VPCPPPSPGP SAVPSSPKSV ATEERAAPST APAEATPPKP GEAEAPPKHP GVLKVEAILE KVQGLEQAVD NFEGKKTDKK YLMIEEYLTK ELLALDSVDP EGRADVRQAR RDGVRKVQTI LEKLEQKAID VPGQVQVYEL QPSNLEADQP LQAIMEMGAV AADKGKKNAG NAEDPHTETQ QPEATAAATS NPSSMTDTPG NPAAP ( SEQ ID NO: 15).
The human BAG 3 protein has the amino acid sequence according to SEQ ID NO: 15.
Example 2.
anti-BAG3 antibodies in CHF patients ' sera
We found that sera from CHF patients recognized BAG3 protein in western blotting, using an anti- human IgG as secondary antibody (results representative of experiments with sera from three different patients are shown in Figure 2A) . This result indicated the presence of anti-BAG3 antibodies in CHF patients' sera. To confirm this finding, we analyzed sera from 50 CHF patients (with ejection fraction < 60%) compared with sera from 50 healthy donors, for the presence of anti- BAG3 antibodies in a specific ELISA test. As shown in Figure 2B, we detected significantly higher values of anti- BAG3 antibodies in patients' compared to controls' sera. ROC analysis of ELISA test results, using as cut-off 0.083 A.U., in 74% sensitivity and 68% specificity (Figure 2C) .
Example 3.
BAG3 binding to macrophages
We addressed the functional significance of BAG3 release by cardiomyocytes . We excluded that the protein could be involved in an autocrine pathway, because it did not apparently bind to the cardiomyocyte surface, as we assessed in experiments using fluorescein isothiocyanate (FITC)- conjugated BAG3 (Figure 3A) . Therefore we investigated whether BAG3 could interact with blood cells. Indeed, we found that FITC-BAG3 bound to macrophages of the cell line J774 (Figure 3B) . BAG3 binding to macrophages was specifically impaired by competing BAG3 peptides or by BAG3-sequestering F(ab')2 fragments from anti- BAG3 monoclonal antibodies (Table I). In particular J774 cells were incubated with 14 nM FITC-BAG3 protein and with 625 nM of BAG3 peptides (peptide 1, peptide 2, peptide 3, peptide 4 or scrambled peptide) or with 420 nM of
F(ab')2 fragments from anti-BAG3 monoclonal and polyclonal antibodies (mouse monoclonal AC1, AC2 and rabbit polyclonal TOS2). F(ab')2 fragments from mouse IgG or F(ab')2 fragments from rabbit
IgG were used as a negative control.
Table I
FITC-rBAG3 FITC-BSA Competiton assays
% of positive % of positive % of positive cells
% inhibition cells ( + S.D.) cells ( + S.D.) ( + S.D.)
FITC-rBAG3 15.7 (±0.45)
FITC-BSA 4.04 (±0.06)
(FITC-rBAG3)-( FITC -BSA) 11.06 (±0.45)
FITC -rBAG3 + Pepl 0.18 (±0.05) 98.4
FITC -rBAG3 + Pep2 1.21(±0.63) 89.1
FITC -rBAG3 + Pep3 5.86 (±0.43) 47.2
FITC -rBAG3 + Pep4 0.68 (±0.20) 93.8
FITC -rBAG3 + Pep Scr 12.1 (±0.21) 0.0
FITC -rBAG3 + Mouse IgG F(ab')2 12.3 (±0.40) 0.0
FITC -rBAG3 + Rabbit IgG F(ab')2 14.7 (±0.20) 0.0
FITC -rBAG3 + AC1 IgG F(ab')2 4.11 (±0.26) 62.8
FITC -rBAG3 + AC2 IgG F(ab')2 3.76 (±0.43) 66.0
FITC -rBAG3 + TOS2 IgG F(ab')2 3.19 (±0.21) 71.1
To explore functional consequences of BAG3 binding to macrophages, we tested the effect of recombinant BAG3 on the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase
(Cox) -2 in the cells. As shown in Figure 3C panel a the levels of those enzymes were enhanced in
BAG3-treated macrophages. Furthermore, BAG3 induced the release of nitrite and interleukin
(IL)- 6 (Figure 3C panels b and c) confirming that macrophages were activated in response to their binding to the protein. In sera from CHF patients we could detect significant amounts of anti-BAG3 antibodies (Figure 2A,B). Autoantibodies production is likely related to the extracellular release of a normally intracellular protein, as happens, for example, in chronic ischaemia patients who produce anti- troponin autoantibodies. ELISA values of anti-BAG3 antibodies in CHF patients' sera are significantly higher than those detected in healthy controls' sera.
Therefore, production of anti-BAG3 antibodies, detected by ELISA, appears a biomarker of chronic heart failure. Its utility for risk stratification and therapy monitoring is worthy of investigation.
BAG3 release by stressed cardiomyocytes and subsequent activation of macrophages, leading to local release of NO, might constitute a protective circuit in heart ischemia. Indeed, vasodilation, neoangiogenesis and remodelling might be targeted. BAG3 release and its transient or chronic effects deserve investigation and could contribute to our understanding of ischemia and other heart stress states.
Furthermore, BAG3- specific mouse monoclonal antibodies AC-1, AC-2 and AC-3 and/or others or same modified as F(ab), F(ab')2, F(ab) or humanized; or peptides comprising sequences PEP 1 to 4 and/or others are molecules able to bind and/or block soluble BAG3 effects to be used for therapy of inflammatory, oncologic or other diseases involving macrophage activation. Example 4.
BAG3 expression in PDAC by immunohistochemistry. We have developed an immunohistochemistry (IHC) kit, including our anti-BAG3 monoclonal antibodies and able to detect BAG3 protein by immunohistochemistry (IHC). This kit revealed BAG3 expression in all the 346 (100%) PDAC biopsies that we analyzed. BAG3 staining revealed a moderate positivity of Langerhans islets, while normal pancreatic ducts and pancreatic acinar cells had no BAG3 expression. This was true in both normal pancreas and non-neoplastic pancreatic tissue adjacent to the tumor mass. BAG3 staining was observed predominantly in the cytoplasm of tumor cells. The intensity of staining of BAG3 was variable as was the number of positive cancer cells. Furthermore, Langerhans insulae were positive and constituted a good internal control of IHC (Figure 4A) . Therefore our kit allows the detection of BAG3 protein in PDAC by IHC. Furthermore, it allows detecting BAG3 protein by IHC also in other tumour or normal tissues
We investigated also the expression of BAG3 in correlation with patients' survival and in response to therapy. We analyzed a cohort of 346 PDAC samples from the same number of patients (Table II) describing data of all tumour samples analyzed by immunohistochemistry and data of the subgroup of R0 patients analyzed with survival data; We assigned a score based on the proportion of positive cancer cells in the sample by counting the number of positive cells over the total cancer cells in 10 non-overlapping fields using a 400x magnification.
Table II
Figure imgf000031_0001
The median percentage of BAG3 positive cells, calculated as described, was 40% and this value was used as a cut-off to separate low and high positive samples. Based on this classification 190 patient samples (55%) were classified as low positive (≤40% of positive cells), and 156 (45%) were classified as high positive (>40% of positive cells) (Figure 4, panel B) . The survival analysis was performed in a cohort of 66 patients of which all the lesions examined were with resection margins free from tumor cells (R0) and only the 3.7% showed the presence of metastases to distant organs (Table II) . Obtained data showed that patients with high BAG3 expression had a significantly shorter survival (median survival = 12.0 months) than those with low BAG3 expression (median survival = 23.0 months), (p = 0.0013) (Figure 4, panel C). Based on Cox proportional analysis high BAG3 expression was associated with a more than two-fold higher risk of death (Table III).
Table III Parameter HR 95% CI p-value
Age (years) 0.99 0.97-1.02 0.601
Sex (M vs. F) 0.86 0.48-1.55 0.617
Tumor grade (G2 vs. Gl)
0.84 0.24-2.98 0.789
Tumor grade (G3 vs. Gl)
1.55 0.45-5.37 0.486
Local tumor stage (T3 vs. T2) 2.5 0.30-21.17 0.400
Nodal stage (Nl vs. NO) 1.17 0.58-2.37 0.668
BAG3 Positivity (High vs. Low) 2.7 1.53-4.78 <0.001 events=66 n=66
Example 5.
BAG3 protein in response to therapy
The first-line chemotherapy for treatment of pancreatic cancer is gemcitabine. In order to investigate the role of BAG3 protein in response to therapy, we analyzed the effect of BAG3 down- modulation in human PDAC cells. We transfected the cells with a specific siRNA targeting bag3 mRNA or with a non specific (NT) siRNA, and treated cells with gemcitabine for the indicated times. Silencing of BAG3 enhanced cell apoptosis in response to the drug (Figure 8) .
These results demonstrate the over expression of BAG3 protein and mRNA in pancreatic adenocarcinoma and the association of high expression levels with a higher risk of death, assigning to BAG3 a role of marker useful for prognosis and therapy choice. Furthermore they show that BAG3 down-modulation enhances apoptosis in PDAC cells. Due to its wide expression in all the lesions tested and to its involvement in sustaining pancreatic cancer cell survival, BAG3 represents a valuable target for innovative therapies in PDAC .
Example 6.
BAG3 protein in sera of pancreatic cancer patients
Because of its wide expression in pancreatic cancer patients, we investigated whether BAG3 was present in sera of pancreatic cancer patients. We found that indeed BAG3 was detectable. Also anti- BAG3 antibodies were detectable, although in prevalence complexed with BAG3. We therefore developed an ELISA test for detecting BAG3/antibody complexes. We analyzed sera from 51 healthy donors and 55 patients affected by PDAC (Table IV) .
Table IV
Figure imgf000033_0001
As shown in Figure 9A, immunocomplexes (measured in arbitrary units) were significantly higher in sera from patients that in those from healthy donors. Furthermore ROC analysis of ELISA test results, using as cut-off 0.183 A.U., in 65% sensitivity and 78% specificity (Figure 9B) .
Example 7.
BAG3 expression by quantitative real-time PCR
The immunohistochemical data on BAG3 expression was also confirmed measuring bag3 mRNA levels in 25 PDAC tissue samples (Table V) . Table V
Figure imgf000034_0001
In particular, there were 16 survivors out of the 25 patients, while 9 patients died of pancreatic cancer progression, at the time of the analysis. The median of expression of bag3 mRNA in tumors analyzed was set at 0.0068 (Ql=0.004; Q3=0.010) (Figure7, panel A) . All the considered demographics and clinical features of PDAC patients were unrelated to bag3 mRNA levels. Thus, correlation with survival was evaluated and the median of bag3 expression levels in PDAC samples was used as a cut-off to separate patients with low from those with high bag3 expression. Thirteen samples (52%) were thus classified as high bag3 positive and 12 samples (48%) as low bag3 positive. Patients with high bag3 expression had shorter survival (median survival =19.0 months) than those with low bag3 expression (median survival = 32.0 months), p- value=0.0198 (Fig 7, panel B) . Based on Cox proportional analysis high bag3 expression was associated with over six fold higher risk of death (univariate: HR=6.094; 95% CI=1.105-33.597, p=0.038) .
bag3 primers that detect BAG3 expression by quantitative real-time RT-PCR. We developed a RT- PCR kit containing specific primers for bag3 mRNA detection and quantification.
Example 8.
We evaluated BAG3 antibodies levels prior to diagnosis of PDAC in a case control study set within the prospective biobank derived from UKCTOCS (Menon et al . , BMJ, 337:a2079, 2008). The trial cohort of 202,000 postmenopausal women donated a single serum at recruitment and 50,000 women continued to donate serum samples annually. Women diagnosed with pancreatic cancer post- randomisation were identified by cancer registry data and postal follow up questionnaires.
For these women diagnosed for PDAC we obtained sera samples at different time points prior PDAC diagnosis. Control sera were obtained from healthy subjects and we measure BAG3 antibody titers in about five control subjects compared to each PDAC case. Furthermore, control sera came from subjects age matched with the respective PDAC case. This control sera matching was used for each time point.
Detection of BAG3-specific antibodies in patients sera from 49 female subjects at 0-1 years pre diagnosis for pancreatic adenocarcinoma were compared with sera from 235 female control subjects sera for the presence of BAG3 specific antibodies in a specific ELISA test.
BAG3 antibodies concentrations were detected in a specific ELISA assay.
As shown in figure 10, BAG3 antibodies were significantly higher in cases at least 3-4 years pre-diagnosis in respect to control subjects. Others time points included: 53 subjects at 1-2 years pre diagnosis for PDAC compared to 251 controls; 44 subjects at 2-3 years pre diagnosis for PDAC compared to 212 controls; 42 subjects at 3-4 years pre diagnosis for PDAC compared to 187 controls .
As shown in figure 10, BAG3 antibodies were significantly higher in cases at least 3-4 years pre-diagnosis in respect to control subjects.
Methods
Cell cultures
HCMa (Human Cardiac Myocytes-adult ) were purchased from Sciencell Research Laboratories (San Diego, CA) and grown in Cardiac Myocyte Medium (CMM, FBS 5%, Cardiac Myocyte Growth Supplement 1%, penicillin/ streptomycin solution 1%) (Sciencell Research Laboratories, San Diego, CA) . All experiments were performed on low- passage cell cultures. Embryonic rat cardiomyoblasts (line H9c2) was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS), 100 U/mL penicillin and 100 g/mL streptomycin. J774A.1, murine monocyte macrophage cell line (ATCC, Manassas, VA, USA), was grown in DMEM supplemented with 10% fetal bovine serum (FBS), 25 mM HEPES, 2 mM glutamine, 100 u/mL penicillin and 100 g/mL streptomycin.
The pancreatic cancer cell lines (MIA PaCa-2, AsPC-1, PSN1, Capan-1 and PANC-1) were received from the American Type Culture Collection (ATCC; Manassas, VA) cell bank. MIA PaCa-2 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) and supplemented with 10% FBS and 2.5% horse serum. AsPC-1 and PSN1 cells were grown in RPMI-1640 Medium supplemented with 10% FBS. Capan-1 were cultured in RPMI-1640 containing 20% FBS while PANC-1 were cultured in DMEM supplemented with 10% FBS. All media for the above cell lines were purchased from BioWhittaker-Lonza (Bergamo, Italy) MediaTech (Manassas, VA) and were supplemented with 100 units of penicillin/mL and 2 g streptomycin/mL ( Sigma-Aldrich, St. Louis, MO). The cells were incubated at 37°C in a 5% CO2 environment. Cells were treated with Gemcitabine (2 ',2'- difluorodeoxycytidine ; GEM, Gemzar®) provided by Eli Lilly (Sesto Fiorentino, Italy) at the indicated concentrations.
Dissociation of BAG3 antibodies in human sera Sera were diluted 1:40 with dissociation buffer (PBS with 1.5% BSA and 0.2 M glycine-acetate pH 2.5) to a 500 μΐ final volume and incubated for 20 min at room temperature. The sera were then pipetted into the sample reservoir of Microcon centrifugal filter device, YM-100 (100,000 MW cut-off; Millipore, Billerica, MA, USA) and centrifuged at 14,100 rpm for 20 min at room temperature. The sample reservoir was then separated from the flow through, placed inverted into a second tube and centrifuged at 5, 000 rpm for 3 min at room temperature. The collected solution containing the antibody dissociated was adjusted to pH 7.0 with 1 M Tris buffer, pH 9.0. The retentate volume was reconstituted to the initial volume (500 μΐ) with dilution buffer ( PBS with 1.5% BSA and 0.1% Tween-20) .14 For detection of BAG3 protein by immunoblotting, the dissociated antibodies were diluted 1:200 in TBST containing 5% bovine serum albumin overnight at 4°C.
Western blot analysis
Cells were harvested and lysed in a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton (TNN buffer) supplemented with a protease inhibitors cocktail (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin) by 3 cycles of freezing and thawing. Soluble proteins were collected after a centrifugation at 10, 000 g for 15 min and their amount was determined by Bradford assay (Bio-Rad, Hercules, CA) . 25 g of total protein and serum samples (1:2 in PBS-T 0.05%) were run on 8% or 10% SDS-PAGE gels and electrophoretically transferred to nitrocellulose membrane.
Nitrocellulose blots were blocked with 10% nonfat dry milk in TBST buffer (20 mM Tris-HCl pH 7.4, 500 mM NaCl, and 0.1% Tween 20) and incubated with primary antibodies in TBST containing 5% bovine serum albumin or 5% non-fat dry milk, overnight at 4°C. Immunoreactivity was detected by sequential incubation with horseradish peroxidase-conjugated secondary antibodies purchased from Pierce (Rockford, IL) and ECL detection reagents purchased from Amersham Life Sciences Inc. (Arlington Heights, IL, USA) .
Scanning densitometry of the bands was performed with an Image Scan (SnapScan 1212; Agfa-Gevaert NV) . The area under the curve related to each band was determined using Gimp2 software. Background was subtracted from the calculated values .
Mass spectrometry
Protein bands were excised and gel pieces were subsequently washed with MilliQ Water and Acetonitrile and the proteins were digested in situ as described in Shevchenko protocol. Briefly, gel slices were reduced in 1,4- dithiothreitol (10 mM) and alkylated with iodoacetamide (50 mM) , then washed and rehydrated in trypsin solution (12 ng/ L) on ice for lh. After the addition of 30 ammonium bicarbonate
(10 mM, pH 7.5), samples were digested overnight at 25 °C. 5 of the obtained peptide mixture were injected onto a nano Acquity LC system (Waters Corp. Manchester, United Kingdom). The peptides were separated on a 1.7 μπι BEH C-18 column (Waters Corp. Manchester, United Kingdom) at a flow rate of 200 nl/min. The gradient (Solution A: 0.1% formic acid, solution B: 0.1% formic acid, 100% ACN) started at 5% and ended at 50% B after 55 min. MS and MS/MS data were acquired using a Q-TOF Premier mass spectrometer (Waters Corp., Micromass, Manchester, United Kingdom) . Doubly and triply charged peptide-ions were automatically chosen by the MassLynx software and fragmented. MS data were automatically processed and peaklists for protein identifications by database searches were generated by the ProteinLynx software. Database searches were carried out with MASCOT server using the SwissProt protein database. The SwissProt human database (405506 sequences; 146166984 residues) was searched allowing 1 missed cleavage, carbamidomethyl (C) as fixed modification. The peptide tolerance was set to 60 ppm and the MS/MS tolerance to 0.8 Da.
Purification of exocytic vesicles by differential ultracentrifugation
Serum-free medium of H9c2 was cleared of cells and large debris by serial centrifugation at 4°C
(2000xg for 15 min, 10, 000xg for 30 min) . After each of the first two centrifugations , pellets are discarded, and the supernatant is kept for the next step. The final supernatant is then ultracentrifuged at 150, 000xg for 90 min at 4°C
(with a SW50.1 rotor, and an Optima L-90K Ultracentrifuge, Beckman Coulter) to pellet exosomes. The pellet is washed in PBS to eliminate contaminating proteins and centrifuged one last time at 150, 000xg for 90 min at 4°C16 After washing, the pellet (exosomes) was resuspended in 20 μΐ of PBS and analyzed with the anti-BAG3 TOS-2 polyclonal antibody in comparison with a whole-cell lysate by western blot. Rab-4 was analyzed as a marker for exocytic vesicles. FACS analysis rBAG3 binding - J774 A.l cells were blocked with 2 % FBS + 0.1 % NaN3 in PBS for 15 min on ice and incubated (2.5 x 105/100 μΐ) with different concentration of FITC-rBAG3 protein (7, 14 and 70 nm) or FITC-BSA (70 nM) in PBS containing 2% FBS+
0.1 % NaN3 for 30 min at 4 °C in the dark. After washing with PBS, the cells were resuspended in PBS + 2% FBS+ 0.1 % NaN3 and analyzed with a FACScan (BD Biosciences) flow cytometer.
Competition - J774 A.l cells (2.5x105/100 μΐ) were incubated with 625 nM of BAG3 peptides (peptide
1, peptide 2, peptide 3, peptide 4 or scrambled peptide) or with 420 nM of F(ab')2 fragments from anti-BAG3 monoclonal and polyclonal antibodies (mouse monoclonal AC1, AC2 and rabbit polyclonal TOS2) or F(ab')2 fragments from mouse IgG or F(ab')2 fragments from rabbit IgG in PBS containing 2% FBS+ 0.1 % NaN3 for 30 min on ice. After incubation the cells were washing with PBS and then were incubated with of FITC-rBAG3 protein (14 nM) , in PBS containing 2% FBS+ 0.1 % NaN3 for 30 min at 4 °C in the dark. After washing with PBS, the cells were resuspended in PBS + 2% FBS + 0.1 % NaN3 and analyzed by flow cytometer (BD Biosciences) .
IL6 detection by ELI SA
IL6 was measured in supernatant of J774 A.l cells (5xl04/ in 96-well microplates) treated with LPS (10 ng/ml) or with rBAG3 (14 nM) or BSA (14 nM) for 10 or 20 hours in absence or presence of polymyxin B sulfate (5 g/ml) . After treatment 50 L of cell culture medium were collected and analyzed in triplicate with a mouse IL6 Kit
(eBioscience) .
Fluorescence
Cells were cultured on coverslips in six-well plates to 60-70% confluence and equal amount of rBAG3-FITC and BSA-FITC proteins were added in HCMa and J774 Al culture media with 0.1 % NaN3 for 1 h. Coverslips were washed in lx PBS and fixed in 3.7% formaldehyde in lx PBS for 30 min at room temperature, and then incubated for 5 min with lx PBS 0.1M glycine. Following incubation with a 1:100 dilution of anti-P-integrin monoclonal antibody at 4 °C, coverslips were washed three times with lx PBS. After incubation with a 1:500 dilution of goat anti-mouse IgG DyLight 594- conjugated antibodies (Jackson ImmunoResearch, West Grove, PA, USA) at room temperature for 45 min, coverslips were again washed for three times in lx PBS. Once incubation with Hoechst 33342 (Sigma Aldrich, 2 g/ml) at room temperature for 10 min, coverslips were again washed for 3 times in PBS and then in distilled water. The coverslips were then mounted on a slide with interspaces containing 47% (v/v) glycerol. Samples were analyzed using a confocal laser scanning microscope (Zeiss LSM confocal microscope, Germany) . Images were acquired in sequential scan mode by using the same acquisitions parameters (laser intensities, gain photomultipliers , pinhole aperture, objective 63X, zoom 2) when comparing experimental and control material. For production of figures, brightness and contrast of images were adjusted by taking care to leave a light cellular fluorescence background for visual appreciation of the lowest fluorescence intensity features and to help comparison among the different experimental groups. Final figures were assembled using Adobe Photoshop 7 and Adobe Illustrator 10. Leica Q9 Confocal Software and ImageJ were used for data analysis.
Measurement of antibody titers by ELISA
NUNC Maxisorp 96 well ELISA plates were coated with recombinant BAG3 protein l g/ml (50 l/well) in PBS, pH 7 and incubated overnight at 4°C. Plates were washed 2 times with washing buffer (PBS + 0.05% Tween-20), and then blocked (150 μΐ/well) for one hour at room temperature with 0.5% fish gelatin in PBS. Following blocking, the plates were washed 2 times with washing buffer and sera were diluted 1:70 with 0.5% fish gelatin in washing buffer and then applied (50 μΐ/well) in triplicate and incubated at room temperature for two hour. The plates were then washed 6 times with washing buffer. Anti-human IgG (H+L) antibody (Sigma Aldrich) was diluted 1:20,000 with 0.5% fish gelatin in washing buffer, added at 50 μΐ/well and incubated at 4°C for 30 minutes. After incubation, the plates were washed 6 times, developed with TMB (50 μΐ/well) (eBioscience ) , the reaction stopped with 4.5 M sulfuric acid (25 μΐ/well) and the plates were analyzed spectrophotometrically at 450 nm.
N02 ~ assay Nitrite content (N02~) , a stable metabolite of NO released by cells in the culture supernatant, was measured in J774 A.l cells (5x104/ in 96-well microplates) treated with LPS (10 ng/ml) or with rBAG3 (7, 14 and 28 nM) or BSA (28 nM) for 24 hours in absence or presence of polymyxin B sulfate (Sigma-Aldrich, St. Louis, MO, USA) 5 g/ml. N02~ amounts were measured by Griess reaction. Briefly, 100 L of cell culture medium were mixed with 100 L of Griess reagent - equal volumes of 1% (w:v) sulphanilamide in 5% (v:v) phosphoric acid and 0.1% (w:v) naphtylethylenediamine-HCl - and incubated at room temperature for 10 min, and then the absorbance was measured at 550 nm in a microplate reader Titertek (Dasit, Cornaredo, Milan, Italy) . The amount of N02- (as μΜ) in the samples was calculated from a sodium nitrite standard curve. Measurement of BAG3/antibody immunocomplexes by ELI SA
NUNC Maxisorp 96 well ELISA plates were coated with anti-BAG3 monoclonal antibody AC-1, AC-2 or AC-3 in PBS, pH 7 and incubated overnight at 4°C. Plates were washed 2 times with washing buffer (PBS + 0.05% Tween-20), and then blocked (150 μΐ/well) for one hour at room temperature with 0.5% fish gelatin in PBS. Following blocking, the plates were washed 2 times with washing buffer and sera were diluted 1:70 with 0.5% fish gelatin in washing buffer and then applied (50 μΐ/well) in triplicate and incubated at room temperature for two hour. The plates were then washed 6 times with washing buffer. Anti-human IgG (H+L) antibody (Sigma Aldrich) was diluted 1:20,000 with 0.5% fish gelatin in washing buffer, added at 50 μΐ/well and incubated at 4°C for 30 minutes. After incubation, the plates were washed 6 times, developed with TMB (50 μΐ/well) (eBioscience ) , the reaction stopped with 4.5 M sulfuric acid (25 μΐ/well) and the plates were analyzed spectrophotometrically at 450 nm.
Immunohistochemistry
Immunohistochemistry protocol included: deparaffination in xylene, re-hydration through descending concentrations of alcohol up to pure water, non-enzymatic antigen retrieval in citrate buffer, pH 6.0, for 30 minutes at 95°C, and endogenous peroxidase quenching with H202 in methanol for 20 minutes. After rinsing with PBS, the samples were blocked with 5% normal horse serum in 0.1% PBS/BSA. To detect BAG3, samples were incubated for 1 hour at room temperature with BAG3 monoclonal antibody AC-1, AC-2 or AC-3 at the concentration of 3 microg/ml. After washing thoroughly with PBS, sections were incubated with a biotinylated secondary anti- mouse IgG for 20 minutes, then rinsed, incubated with avidin-biotin-complexes peroxidase
(purchased from Novocastra-Leica Microsystems, Milano, IT) and developed with diaminobenzidine
( Sigma-Aldrich, St. Louis, MO). Finally, the sections were counterstained with hematoxylin, dehydrated in alcohol, cleared in xylene, and mounted with Permount (Fisher Scientific, Milan, IT) .
Quantitative Real-time RT-PCR
Tissue specimens of resected pancreatic cancer were taken, immediately frozen in liquid nitrogen, and stored at -80°C until RNA extraction. Total RNA was isolated from frozen tissues and from pancreatic cancer cell lines by means of phenol extraction (TRIzol Reagent, Invitrogen Corporation, Carlsbad, CA, USA) . In tissue samples Cancer cellularity was enriched by cryostat sectioning and dissection of most cellular areas . RNA concentration and purity (A260 : A280>2.0; A260/A230>1.8 ) were validated by NanoDrop Spectrophotometer (Thermo Fisher, Waltham, MA, USA). 1.0 g of total RNA was reverse- transcribed using the High-Capacity cDNA Reverse Transcription Kit according to the manufacturer's instructions (Applied Biosystems, Applera, Foster City, CA, USA) . Quantitative real-time PCR assay was used to assess the differential expression of BAG3 in tumor tissue samples. Primers for the human bag3 gene were synthesized by Primm srl (Milano, Italy) (forward primer: (SEQ ID NO: 16) CCT GTT AGC TGT GGT TG; reverse primer: (SEQ ID NO: 17) AAC ATA CAG ATA TTC CTA TGG C) . All qPCRs were performed in a 25- μΐ final volume, in three replicates per sample, by using QuantiFast SYBR Green PCR kit (QIAGEN, Hamburg, Germany) and run in an ABI PRISM® 7700 Sequence Detection System (Applied Biosystems, Applera, Foster City, CA, USA) according to the following conditions: 95° C for 5 min, 40 cycles at 95° C for 10 s and at 60° C for 30 sec. Data were acquired as threshold cycle (Ct) value using the S.D.S software v 2.1. In each sample, bag3 mRNA relative expression levels was obtained using the comparative method, after normalizing for the expression of the endogenous GAPDH.
From the above description and the above- noted examples, the advantage attained by the biological markers described and obtained according to the present invention are apparent .

Claims

1. Anti-BAG-3 antibodies for use in the diagnosis of a pathological state.
2. Anti-BAG-3 antibodies for use according to claim 1, wherein said anti-BAG-3 antibodies are bound to soluble BAG3 to form immune complexes .
3. Anti-BAG-3 antibodies for use according to anyone of claims 1 or 2, wherein said diagnosis is in vitro or ex vivo.
4. Anti-BAG-3 antibodies for use according to anyone of claims 1 or 3, wherein the recipient of said diagnosis is a mammalian, preferably a human .
5. Anti-BAG-3 antibodies for use according to anyone of claims 1 or 4, wherein said pathological state is selected from: heart disease, cancer, diabetes, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues .
6. Anti-BAG-3 antibodies for use according to claim 5 wherein said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
7. Anti-BAG-3 antibodies for use according to claim 5 wherein said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer .
8. Method for detecting the presence of an anti- BAG3 antibody or an anti-BAG3 antibody bound to soluble BAG3 to form an immune complex in a biological sample, comprising the step of: a. obtaining a biological sample, consisting of serum, plasma, urine or saliva.
b. determining the presence of anti-BAG3 or BAG3 associated antibodies in the biological sample .
9. Method according to claim 8, further comprising the step of:
c. comparing the values obtained from biological sample with reference values or with the values obtained from healthy donors .
10. Method according to anyone of claims 6 or 9, wherein said determination step b. is performed by an ELISA test.
11. Method according to anyone of claims 6 to 10, wherein said serum, plasma, urine or saliva is from a mammalian, preferably a human.
12. Method according to anyone of claims 6 to 11, wherein the presence of said anti-BAG3 antibody or said immune complex is associated with a pathological condition.
13. Method according to claim 12, wherein said pathological condition is selected from: heart disease, cancer, inflammation and inflammatory related diseases of the skin, nerves, bones, blood vessels and connective tissues.
14. Method according to claim 13, wherein said heart disease is selected from: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, acute coronary disease, ischemia, acute heart failure, chronic heart failure or iatrogenic heart disease .
15. Method according to claim 13, wherein said cancer is selected from: pancreatic cancer, bladder cancer and prostate cancer.
16. Use of an ELISA kit, comprising a BAG3 recombinant protein or BAG3-specific mouse monoclonal antibodies AC-1, AC-2 AC-3, AC-4 and AC-5 for capturing soluble BAG3 and antibodies able to recognize human immunoglobulins, for the detection of anti- BAG3 antibodies or anti-BAG3 antibodies bound to soluble BAG3 to form an immune complexes in a biological sample.
17. Use according to claim 16, wherein said biological sample is a serum, plasma, urine or saliva sample.
18. Use according to claim 17, wherein said serum, plasma, urine or saliva sample is from a mammalian, preferably a human.
PCT/EP2013/061976 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker WO2013189778A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020157001313A KR102150903B1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker
PL13728180T PL2861618T3 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker
CN201380032138.3A CN104507965B (en) 2012-06-19 2013-06-11 BAG3 as serum and biochemical marker
AU2013279604A AU2013279604B2 (en) 2012-06-19 2013-06-11 BAG3 as biochemical serum and tissue marker
BR112014031958A BR112014031958A2 (en) 2012-06-19 2013-06-11 bag3 as tissue marker and biochemical serum
CA2876922A CA2876922C (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker
JP2015517672A JP6654432B2 (en) 2012-06-19 2013-06-11 BAG3 as a biochemical serum marker and tissue marker
EP13728180.4A EP2861618B1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker
ES13728180T ES2795981T3 (en) 2012-06-19 2013-06-11 BAG3 as a serum and tissue biochemical marker
IN10561DEN2014 IN2014DN10561A (en) 2012-06-19 2014-12-11
US14/572,654 US10359433B2 (en) 2012-06-19 2014-12-16 BAG3 as biochemical serum and tissue marker

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12172531.1A EP2676966A1 (en) 2012-06-19 2012-06-19 BAG3 as biochemical serum and tissue marker
EP12172531.1 2012-06-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/572,654 Continuation US10359433B2 (en) 2012-06-19 2014-12-16 BAG3 as biochemical serum and tissue marker

Publications (1)

Publication Number Publication Date
WO2013189778A1 true WO2013189778A1 (en) 2013-12-27

Family

ID=48607259

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2013/061971 WO2013189775A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker
PCT/EP2013/061976 WO2013189778A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/061971 WO2013189775A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Country Status (12)

Country Link
US (2) US10359433B2 (en)
EP (3) EP2676966A1 (en)
JP (2) JP6654432B2 (en)
KR (2) KR20150036102A (en)
CN (2) CN104507965B (en)
AU (2) AU2013279604B2 (en)
BR (2) BR112014031957A2 (en)
CA (2) CA2876922C (en)
ES (1) ES2795981T3 (en)
IN (2) IN2014DN10561A (en)
PL (1) PL2861618T3 (en)
WO (2) WO2013189775A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130403A1 (en) * 2013-03-18 2014-09-19 Biouniversa Srl ANTI-BAG3 ANTIBODIES FOR THERAPEUTIC USE
CN105021825B (en) * 2015-07-09 2016-08-17 陈勇 A kind of ELISA kit detecting cancer of pancreas related polypeptide DAP44
CN105769900A (en) * 2016-03-22 2016-07-20 山西大学 Application of BAG3 gene to preparation of bladder cancer resisting medicines
IT201600069391A1 (en) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno USE OF BAG3 PROTEIN AND ITS PEPTIDAL FRAGMENTS FOR THE CONTROL OF VASCULAR HOMEOSTASIS
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN113862361B (en) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 Molecular marker HSF1 for diagnosing and treating bladder cancer and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2011067377A1 (en) * 2009-12-04 2011-06-09 Biouniversa S.R.L. Biochemical serum marker
WO2012049664A2 (en) * 2010-10-15 2012-04-19 Sense Proteomic Limited Auto-antigen biomarkers for lupus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
WO2001004343A2 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
EP1438583B1 (en) * 2001-09-20 2009-09-16 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
WO2011044927A1 (en) * 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the diagnosis or prognosis of an advanced heart failure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2011067377A1 (en) * 2009-12-04 2011-06-09 Biouniversa S.R.L. Biochemical serum marker
WO2012049664A2 (en) * 2010-10-15 2012-04-19 Sense Proteomic Limited Auto-antigen biomarkers for lupus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. FESTA ET AL.: "BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy.", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 178, no. 6, 10 May 2011 (2011-05-10), USA, pages 2504 - 2512, XP002685427 *
MARCO M; TURCO MC; ROSATI A: "BAG3 protein is induced during cardiomyoblast differentiation and modulates myogenin expression", CELL CYCLE, vol. 10, 2011, pages 850 - 852
MENON ET AL., BMJ, vol. 337, 2008, pages A2079
ROSATI A; GRAZIANO V; DE LAURENZI V; PASCALE M; TURCO MC, CELL DEATH DIS, vol. 2, 2011, pages E141

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors

Also Published As

Publication number Publication date
IN2014DN10561A (en) 2015-08-28
US10359433B2 (en) 2019-07-23
CA2876922A1 (en) 2013-12-27
ES2795981T3 (en) 2020-11-25
EP2861618A1 (en) 2015-04-22
WO2013189775A1 (en) 2013-12-27
EP2676966A1 (en) 2013-12-25
KR20150036102A (en) 2015-04-07
JP2015529633A (en) 2015-10-08
CN104619861A (en) 2015-05-13
AU2013279601A1 (en) 2015-01-15
CA2876872A1 (en) 2013-12-27
KR20150036111A (en) 2015-04-07
US20150132764A1 (en) 2015-05-14
AU2013279604A1 (en) 2014-12-18
BR112014031957A2 (en) 2017-08-01
CN104507965B (en) 2019-04-26
PL2861618T3 (en) 2020-09-21
EP2861618B1 (en) 2020-03-11
CN104507965A (en) 2015-04-08
CA2876922C (en) 2022-09-20
BR112014031958A2 (en) 2017-08-01
IN2014DN10562A (en) 2015-08-28
JP6654432B2 (en) 2020-02-26
KR102150903B1 (en) 2020-09-03
AU2013279604B2 (en) 2018-03-29
EP2861754A1 (en) 2015-04-22
JP2015521475A (en) 2015-07-30
US20150147767A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
US10359433B2 (en) BAG3 as biochemical serum and tissue marker
ES2415375T3 (en) A procedure to diagnose atherosclerotic plaques by measuring CD36
CN106461681B (en) Biomarker and application thereof for diagnosing vascular diseases
JP5946937B2 (en) Blocking CCL18 signaling through CCR6 as a treatment option in fibrotic diseases and cancer
JP2018532100A (en) Vacuum blood collection tubes containing protease inhibitors for evaluation of contact system activation
JP7073528B2 (en) Biomarkers for classifying allogeneic transplant recipients
CN112557664A (en) Application of CRYAB in acute kidney injury detection and detection kit
WO2020205299A1 (en) Detecting cancer biomarker proteins in blood
US9182413B2 (en) Methods and devices for diagnosing cardiac disorders
AU2012271293B2 (en) Biomarkers for epithelial cancer diagnosis and treatment
Jeong et al. GCC2 is a New Biomarker for Diagnosis of Early Non-Small Cell Lung Cancer and A Potential Target to Reverse Epithelial to Mesenchymal Transition
CN117106894A (en) Application of NKRF in diagnosis and treatment of pathological heart reconstruction
Tapken et al. The Trojan Horse of Inflammation: Extracellular Vesicles and their Functionally Active Receptors
Carreras-Planella Study of urine extracellular vesicles-derived protein biomarkers for the non-invasive monitoring of kidney-transplanted patients
CN117491634A (en) LDHA + Application of EVs as biomarker in prediction, detection and evaluation of recurrence risk after brain glioma operation
CN116832160A (en) Application of Abeta 1-42 in preparation of preeclampsia treatment drugs or diagnostic kit
KR20200135994A (en) How to diagnose heart muscle damage
JP2013545992A (en) Biomarker, use of biomarker and method for identifying biomarker
US20140335090A1 (en) Therapeutic agent for cancer, and method for determining prognosis of cancer
WO2008093083A2 (en) Prognostic markers for hpv-related cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13728180

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013728180

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2876922

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013279604

Country of ref document: AU

Date of ref document: 20130611

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015517672

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20157001313

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014031958

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014031958

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141219